G
Gianfranco Delle Fave
Researcher at Sapienza University of Rome
Publications - 101
Citations - 6466
Gianfranco Delle Fave is an academic researcher from Sapienza University of Rome. The author has contributed to research in topics: Neuroendocrine tumors & Everolimus. The author has an hindex of 36, co-authored 101 publications receiving 5628 citations. Previous affiliations of Gianfranco Delle Fave include University of Parma & Health Science University.
Papers
More filters
Journal ArticleDOI
Gastroenteropancreatic neuroendocrine tumours.
Irvin M. Modlin,Kjell Öberg,Daniel C. Chung,Robert T. Jensen,Wouter W. de Herder,Rajesh V. Thakker,Martyn Caplin,Gianfranco Delle Fave,Greg Kaltsas,Eric P. Krenning,Steven F. Moss,Ola Nilsson,Guido Rindi,Ramon Salazar,Philippe Ruszniewski,Anders Sundin +15 more
TL;DR: To improve outcome from GEP NETs, a better understanding of their biology is needed, with emphasis on molecular genetics and disease modeling, and more-reliable serum markers, better tumour localisation and identification of small lesions, and histological grading systems and classifications with prognostic application are needed.
Journal ArticleDOI
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
James C. Yao,Nicola Fazio,Simron Singh,Roberto Buzzoni,Carlo Carnaghi,Edward M. Wolin,Jiri Tomasek,Markus Raderer,Harald Lahner,Maurizio Voi,Lida Bubuteishvili Pacaud,Nicolas Rouyrre,Carolin Sachs,Juan W. Valle,Gianfranco Delle Fave,Eric Van Cutsem,Margot E T Tesselaar,Yasuhiro Shimada,Do Youn Oh,Jonathan R. Strosberg,Matthew H. Kulke,Marianne Pavel +21 more
TL;DR: Everolimus is the first targeted agent to show robust anti-tumour activity with acceptable tolerability across a broad range of neuroendocrine tumours, including those arising from the pancreas, lung, and gastrointestinal tract.
Journal ArticleDOI
Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients.
Aldo Scarpa,William Mantovani,Paola Capelli,Stefania Beghelli,Letizia Boninsegna,Rossella Bettini,Francesco Panzuto,Paolo Pederzoli,Gianfranco Delle Fave,Massimo Falconi +9 more
TL;DR: The modified TNM described in this study ameliorates the clinical applicability and prediction of outcome of the ENETS–TNM and assigns a risk of death proportional to the stage at the time of diagnosis, and allows a clinically based staging of patients, as the T parameters as modified permit their clinical-radiological recognition.
Journal ArticleDOI
Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained by EUS-guided fine-needle tissue acquisition: a prospective study
Alberto Larghi,Gabriele Capurso,Antonella Carnuccio,Antonella Carnuccio,Riccardo Ricci,Sergio Alfieri,Domenico Galasso,Francesca Lugli,Antonio Bianchi,Francesco Panzuto,Laura De Marinis,Massimo Falconi,Gianfranco Delle Fave,Giovanni Battista Doglietto,Guido Costamagna,Guido Rindi +15 more
TL;DR: In patients with suspected nonfunctioning low-grade to intermediate-grade pancreatic neuroendocrine tumors (p-NETs), retrieval of tissue specimens with EUS-FNTA by using a 19-gauge needle is safe, feasible, and highly accurate for both diagnosis and Ki-67 determination.
Journal ArticleDOI
Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections.
Letizia Boninsegna,Francesco Panzuto,Stefano Partelli,Paola Capelli,Gianfranco Delle Fave,Rossella Bettini,Paolo Pederzoli,Aldo Scarpa,Massimo Falconi +8 more
TL;DR: After resection for malignant PNETs, LNR and a Ki67 >5% are the most powerful predictors of recurrence and the presence of these factors should be considered for addressing patients to adjuvant treatment in future clinical trials.